CLINICAL TRIALS PROFILE FOR ARIMIDEX

All Clinical Trials for Arimidex

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00005908 ↗	Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer	Completed	National Cancer Institute (NCI)	Phase 2	2000-06-01	This study will assess the usefulness of a technique called complementary deoxyribonucleic acid (cDNA) microarray-an examination of a wide array of genes to identify disease-associated patterns-for measuring tumor response to chemotherapy in breast cancer patients. The study will look for "markers" that can help select the most effective type of chemotherapy. It will also evaluate the safety and effectiveness of a new drug combination of capecitabine and docetaxel. Patients age 18 years and older with stage II or III breast cancer whose tumor is 2 centimeters or larger may be eligible for this study. Those enrolled will be treated with surgery, standard chemotherapy using doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan), and the capecitabine and docetaxel combination. Patients will have a physical examination, mammogram and magnetic resonance imaging to evaluate their tumor before beginning treatment. They will then have four 21-day treatment cycles of docetaxel and capecitabine, as follows: docetaxel intravenously (through a vein) on day 1 and capecitabine pills (by mouth) twice a day from days 2 through 15. No drugs will be given from days 16 through 21. This regimen will be repeated four times, after which the tumor will be re-evaluated by physical examination, mammogram, and magnetic resonance imaging. Patients will then have surgery to remove the cancer-either lumpectomy with removal of the underarm lymph nodes; mastectomy and removal of the underarm lymph nodes; or modified radical mastectomy. After recovery, they will have four more cycles of chemotherapy, this time with a doxorubicin and cyclophosphamide. Both drugs will be given intravenously on day 1 of four 21-day cycles. Some patients who had a mastectomy (depending on their tumor characteristics and whether tumor cells were found in their lymph nodes) and all those who had a lumpectomy will also have radiation therapy. Patients with hormone receptor-positive tumors will also receive tamoxifen treatment for 5 years. In addition to the above procedures, all patients will have tumor biopsies (removal of a small piece of tumor tissue) before beginning treatment, on day 1 of cycle 1, before cycle 2, and at the time of surgery, and physical examinations, chest X-rays, bone scans, computerized tomography (CT) scans, electrocardiograms, multi-gated acquisition scan-MUGA (nuclear medicine test of cardiac function) or echocardiograms of heart function, mammograms and blood tests at various times during the study. Patients will be followed at National Institutes of Health (NIH) for 3 years after diagnosis with physical examinations, blood tests, X-rays, and computed tomography (CT) scans. Although it is not known whether this treatment will help an individual patient's cancer, possible benefits are tumor shrinkage and decreased risk of disease recurrence. In addition, the information gained about genetic changes after chemotherapy will help determine if additional studies on the use of cDNA microarray to measure tumor response are warranted.
NCT00022672 ↗	A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer	Completed	Genentech, Inc.	Phase 3	2001-01-01	This 2 arm study assessed the safety and efficacy of adding intravenous trastuzumab (Herceptin®) to daily oral anastrozole (Arimidex®) tablets as first- and second-line treatment in postmenopausal patients with human epidermal growth factor receptor-2 (HER2) overexpressing metastatic breast cancer (ER+ve and/or PR+ve). Patients were randomized to receive either anastrazole 1 mg per os (po) daily, or anastrazole 1 mg po daily + a loading dose of Herceptin® 4 mg/kg intravenous (iv) followed by weekly doses of Herceptin® 2 mg/kg iv. The anticipated time on study treatment was until disease progression, and the target sample size was 100-500 individuals.
NCT00022672 ↗	A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer	Completed	Hoffmann-La Roche	Phase 3	2001-01-01	This 2 arm study assessed the safety and efficacy of adding intravenous trastuzumab (Herceptin®) to daily oral anastrozole (Arimidex®) tablets as first- and second-line treatment in postmenopausal patients with human epidermal growth factor receptor-2 (HER2) overexpressing metastatic breast cancer (ER+ve and/or PR+ve). Patients were randomized to receive either anastrazole 1 mg per os (po) daily, or anastrazole 1 mg po daily + a loading dose of Herceptin® 4 mg/kg intravenous (iv) followed by weekly doses of Herceptin® 2 mg/kg iv. The anticipated time on study treatment was until disease progression, and the target sample size was 100-500 individuals.
NCT00049062 ↗	Anastrozole and ZD 1839 in Treating Postmenopausal Women With Metastatic Breast Cancer	Completed	The University of Texas Health Science Center at San Antonio	Phase 2	2002-09-01	RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Anastrozole may fight breast cancer by blocking the production of estrogen by the tumor cells. Biological therapies such as ZD 1839 may interfere with the growth of the tumor cells and slow the growth of advanced solid tumors. Combining anastrozole with ZD 1839 may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining anastrozole with ZD 1839 in treating postmenopausal women who have metastatic breast cancer that has not responded to hormone therapy.
NCT00055302 ↗	Arimidex in McCune Albright Syndrome	Completed	AstraZeneca	Phase 2	2002-08-01	The primary objective of this study is to evaluate the safety and efficacy of anastrozole 1 mg given once daily in subjects with McCune-Albright Syndrome.
NCT00057941 ↗	Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer	Completed	National Cancer Institute (NCI)	Phase 2	2003-09-01	This randomized phase II trial is studying how well giving gefitinib together with anastrozole works compared to giving gefitinib together with fulvestrant in treating postmenopausal women with recurrent or metastatic breast cancer. Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using anastrozole and fulvestrant may fight breast cancer by blocking the use of estrogen. Gefitinib (ZD1839) may stop the growth of cancer cells by blocking the enzymes necessary for their growth. It is not yet known whether gefitinib is more effective when combined with anastrozole or fulvestrant in treating breast cancer.

Clinical Trial Conditions for Arimidex

Condition Name

Condition Name for Arimidex
Intervention	Trials
Breast Cancer	67
Stage IV Breast Cancer	8
Recurrent Breast Cancer	7
Breast Neoplasms	7

Condition MeSH

Condition MeSH for Arimidex
Intervention	Trials
Breast Neoplasms	112
Carcinoma	12
Breast Neoplasms, Male	4
Neoplasms	4

Clinical Trial Locations for Arimidex

Trials by Country

Trials by Country for Arimidex
Location	Trials
United States	420
Japan	43
Canada	36
Spain	30
United Kingdom	24

Trials by US State

Trials by US State for Arimidex
Location	Trials
Massachusetts	21
California	20
Florida	18
Texas	18
Maryland	16

Clinical Trial Progress for Arimidex

Clinical Trial Phase

Clinical Trial Phase for Arimidex
Clinical Trial Phase	Trials
Phase 4	6
Phase 3	38
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for Arimidex
Clinical Trial Phase	Trials
Completed	78
Recruiting	20
Terminated	20

Clinical Trial Sponsors for Arimidex

Sponsor Name

Sponsor Name for Arimidex
Sponsor	Trials
AstraZeneca	54
National Cancer Institute (NCI)	21
Pfizer	9

Sponsor Type

Sponsor Type for Arimidex
Sponsor	Trials
Other	154
Industry	112
NIH	29

Arimidex Market Analysis and Financial Projection

Last updated: April 28, 2026

Arimidex (anastrozole): Clinical Trials Update, Market Analysis, and Projection

What is Arimidex and what markets does it address?

Arimidex is anastrozole, an aromatase inhibitor used for hormone receptor-positive breast cancer in postmenopausal patients, including:

• Adjuvant treatment of early-stage breast cancer
• Treatment of advanced/metastatic breast cancer
• Extended adjuvant strategies in eligible patients (practice varies by regimen and guideline era)

In markets where Arimidex is sold as a brand, utilization has progressively shifted to generic anastrozole, compressing unit pricing but sustaining volume due to broad guideline use. The key commercial variable is not clinical differentiation; it is brand erosion, payer formularies, and generic price levels.

---

How do current clinical development and late-stage evidence look?

No ongoing late-stage registrational program for a new Arimidex (anastrozole) indication is indicated by the public regulatory trial record in a way that would restart market share through incremental efficacy. The remaining clinical activity around anastrozole is concentrated in:

• Adjuvant duration comparisons and sequencing strategies (historically)
• Real-world outcomes and comparative safety effectiveness
• Biomarker and subpopulation analyses (mostly translational/observational)

Key reference endpoints from the established evidence base include disease-free survival (DFS) and overall survival (OS) in postmenopausal hormone receptor-positive settings supported by major randomized datasets in the adjuvant landscape (AI versus prior hormonal approaches and extended adjuvant comparisons). FDA labeling and major guideline summaries anchor these claims.

Regulatory positioning. FDA product labeling remains centered on the standard of care role for postmenopausal hormone receptor-positive breast cancer, with use statements aligned to approved indications and the established benefit-risk profile. [1]

---

What is the current market status for anastrozole and Arimidex?

Arimidex competes in a mature endocrine oncology market where patent expiry and generic competition dominate price formation. The commercial reality is that the therapeutic class is entrenched, but brand pricing power is limited.

Commercial drivers

• Persistent guideline use of aromatase inhibitors in eligible postmenopausal HR+ disease
• Generic supply lowering average selling prices
• Payer step-editing and formulary preferences favoring the lowest-cost equivalent, usually generic anastrozole
• Ongoing mix shift with competing AIs (letrozole, exemestane) and in some settings treatment sequencing

Market demand anchor

• Breast cancer incidence and the fraction of hormone receptor-positive disease create a stable demand base.
• AI selection depends on tolerability (e.g., arthralgia, bone effects), cost, and persistence rates.

Market growth pattern

• Volume demand tends to grow slowly with epidemiology.
• Value growth is constrained by generic price compression unless the analyst assumes substitution toward higher-priced competitors or regional reimbursement changes.

---

How should investors and business teams project volume, pricing, and revenue?

Because Arimidex is effectively a brand-with-generic parity in most mature geographies, projection frameworks should treat the brand as sensitive to share shifts and pricing benchmarks rather than to trial-driven step changes.

Projection framework (mechanistic)

Revenue = Units × Net Price

1) Units

• Linked to postmenopausal HR+ breast cancer treatment patterns and persistence.
• Stabilizes with guideline adherence and incidence growth.
• Erodes only if clinical practice shifts strongly toward other endocrine options or chemotherapy rebalancing.

2) Net price

• Set by generic competition intensity and payer reimbursement.
• Brand net price tracks a premium band that typically narrows over time with formulary pressure.

3) Competitive mix

• Relative dynamics between anastrozole, letrozole, and exemestane affect switching and dose persistence.
• Safety profiles impact adherence, but head-to-head incremental survival differences are not enough to override cost in most payer settings.

Scenario model

Use three scenarios to stress test value, not efficacy:

• Base case: stable units, steady generic-driven price erosion continues
• Upside: slower brand share loss due to contracting behavior or channel inventory dynamics
• Downside: accelerated share drift and deeper price compression

The resulting implication is straightforward: market growth is primarily volume-stable and value-constrained. Under generic competition, meaningful revenue inflection usually requires a branding or differentiated-care pathway rather than a new clinical claim.

---

What is the role of FDA labeling and safety considerations in prescribing persistence?

FDA labeling defines the approved use in postmenopausal HR+ breast cancer and includes standard cautions tied to aromatase inhibition class risks:

• Bone mineral density loss and need for monitoring and management in clinical practice
• Musculoskeletal symptoms and tolerability management
• Hepatic considerations and other class safety items as described in label language

These points matter for projection because persistence rates influence units over treatment duration. FDA labeling is the anchor document for what physicians can do under the approved indication and how safety monitoring influences real-world continuity. [1]

---

What is the practical “clinical update” that affects market behavior right now?

For a mature, generic-dominated product, the “clinical update” that moves the market is usually one of:

• Guideline updates affecting AI selection and duration
• New comparative effectiveness evidence shifting adherence or switching
• Payer policy updates changing preferred AI lists
• Safety-monitoring program adoption reducing discontinuation

For Arimidex/anastrozole, the dominant ongoing behavior is continued reliance in postmenopausal HR+ disease, while competitive and payer pressures determine net revenue.

---

Market projection summary

Base-case view (high confidence for value constraints):

• Units remain supported by incidence and guideline adherence in postmenopausal HR+ breast cancer.
• Brand revenue is structurally limited by generic anastrozole substitution.
• Value growth lags volume growth because pricing converges toward generic benchmarks.

Investment implication:

• Arimidex is better modeled as a mature franchise with price erosion than as a growth engine driven by new clinical programs.
• Any upside comes from share retention in specific channels/geographies, not from a new clinical differentiation wave.

---

Key Takeaways

• Arimidex (anastrozole) is a mature aromatase inhibitor used in postmenopausal HR+ breast cancer with FDA labeling anchored to established adjuvant and advanced disease roles. [1]
• Current public clinical activity does not show a clear registrational, Arimidex-specific pathway that would materially reset market share through new indication-level differentiation.
• Market value is constrained by generic substitution; projections should treat growth as volume-stable and net price-depressed.
• The highest-impact levers for brand performance are payer formulary position, channel contracting, persistence driven by tolerability management, and competition among AIs.

---

FAQs

1) Does Arimidex have an active late-stage registrational trial that could restart growth?
No public signal indicates a new Arimidex-led registrational program that would materially change the approved label role.

2) What patient population drives demand most directly?
Postmenopausal patients with hormone receptor-positive breast cancer, for adjuvant and advanced disease use cases under established guidelines and labeling. [1]

3) What most affects revenue going forward, efficacy or pricing?
Pricing and formulary behavior dominate because generic anastrozole limits brand premium in mature markets.

4) Which safety elements can influence persistence and thus unit demand?
Bone health monitoring and musculoskeletal tolerability are key real-world adherence factors tied to the aromatase inhibitor class and reflected in label-related cautions and standard practice. [1]

5) How should a projection model be structured for Arimidex?
Use Units × Net Price, with Units tied to persistence and incidence and Net Price tied to generic penetration and payer contracting dynamics.

---

References

[1] U.S. Food and Drug Administration. Arimidex (anastrozole) prescribing information. FDA access data. https://www.accessdata.fda.gov/